Adma Biologics Inc (ADMA) concluded trading on Thursday at a closing price of $21.60, with 3.63 million shares of worth about $78.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 13.62% during that period and on June 12, 2025 the price saw a loss of about -1.23%. Currently the company’s common shares owned by public are about 238.53M shares, out of which, 230.40M shares are available for trading.
Stock saw a price change of 8.32% in past 5 days and over the past one month there was a price change of 8.65%. Year-to-date (YTD), ADMA shares are showing a performance of 25.95% which increased to 106.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.21 but also hit the highest price of $25.67 during that period. The average intraday trading volume for Adma Biologics Inc shares is 3.49 million. The stock is currently trading 6.35% above its 20-day simple moving average (SMA20), while that difference is up 3.77% for SMA50 and it goes to 14.99% higher than SMA200.
Adma Biologics Inc (NASDAQ: ADMA) currently have 238.53M outstanding shares and institutions hold larger chunk of about 86.39% of that.
The stock has a current market capitalization of $5.16B and its 3Y-monthly beta is at 0.48. PE ratio of stock for trailing 12 months is 25.59, while it has posted earnings per share of $0.84 in the same period. Its PEG reads 0.63 and has Quick Ratio of 3.36 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADMA, volatility over the week remained 2.58% while standing at 2.01% over the month.
Stock’s fiscal year EPS is expected to rise by 34.67% while it is estimated to increase by 49.75% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 19, 2023 offering a Strong buy rating for the stock and assigned a target price of $5 to it. Coverage by Mizuho stated Adma Biologics Inc (ADMA) stock as a Buy in their note to investors on October 13, 2022, suggesting a price target of $5 for the stock. On November 11, 2021, Raymond James Upgrade their recommendations, while on November 09, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $4.50. Stock get a Buy rating from Jefferies on June 04, 2019.
